Hormone Replacement for Male Hypogonadism

This medication is commonly used as Hormone Replacement Therapy (HRT) in adult males who have a clinically confirmed deficiency or absence of natural testosterone, a condition known as male hypogonadism. The treatment is applied to address a cluster of chronic symptoms related to systemic imbalance, including low sexual desire (libido), persistent fatigue, and general lethargy. This medication is relevant for use in conditions such as male hypogonadism, delayed puberty in adolescent males, and specific cases of advancing metastatic mammary cancer in postmenopausal women. The therapy supports easing the overall symptom load for patients experiencing these systemic symptoms.

“It is applied across domains where additional symptomatic support is needed.”

---

Support for Physical Structure and Functional Stability

Testosterone replacement supports the patient and is relevant for easing the symptoms related to physical discomfort associated with deficiency. This generally covers symptoms like reduced muscle bulk and strength and diminished bone mineral density. The therapeutic benefit may assist with maintaining functional stability and lean body mass, supporting general well-being and long-term skeletal health. In adolescents, this injection is commonly used in a specific, short-term context to support pubertal development.

Quick Fact: Support for Systemic Imbalance The medication is applied across domains where additional symptomatic support is needed, primarily addressing symptoms related to hormonal deficiency and physical decline.

Regulatory References

1. NIH MedlinePlus Drug Information

This medicine is officially intended for adult men diagnosed with a deficiency or absence of natural testosterone, known as Primary or Hypogonadotropic hypogonadism.

Contraindicated Populations

Use is absolutely prohibited in men with known or suspected carcinoma of the prostate or male breast cancer. The medicine is also contraindicated in women who are pregnant or breastfeeding due to the risk of harm, and in any patient with a known hypersensitivity to testosterone enanthate or its excipients.

Age and Condition Restrictions

Safety and efficacy have not been established in males under 18 years of age. Use in geriatric patients (over 65) is subject to specific risk assessment due to insufficient long-term safety data.

Restricted use is required for patients with pre-existing cardiac, renal, or hepatic disease due to the risk of fluid retention. Patients with severe insufficiency of these organs must discontinue treatment immediately if complications occur. Use is also restricted in men with Benign Prostatic Hyperplasia (BPH), who require close monitoring for symptom worsening.

The officially documented interaction profile for Testosteron-Depot EIFELFANGO is defined by specific pharmacokinetic and pharmacodynamic patterns, as stated in government regulatory labeling.

Documented Drug–Drug Interactions

1. Effects on Oral Anticoagulants Co-administration with oral anticoagulants (such as warfarin and other coumarin derivatives) may result in a change in anticoagulant activity, leading to an increased effect. This interaction necessitates more frequent procedural monitoring of the International Normalized Ratio (INR) and prothrombin time.

2. Interactions with Antidiabetics Androgens may decrease blood glucose levels. When administered with hypoglycaemics or antidiabetic medicines (including insulin), this action can enhance the blood-sugar-lowering effect of the antidiabetic agent, which regulatory documents note may require an adjustment to the antidiabetic dosage.

3. Pharmacodynamic Effects and Fluid Retention Use with corticosteroids (or ACTH) may result in increased fluid retention (edema). Additionally, co-administration with medications known to increase blood pressure may lead to additive increases in blood pressure.

4. Pharmacokinetic Clearance The medicine is subject to a pharmacokinetic interaction with microsomal enzyme inducers (such as barbiturates). These substances are formally documented to increase the rate of testosterone clearance from the body, consequently reducing the systemic exposure of the active compound.

Population-Specific Caution

Regulatory information highlights that the fluid retention interaction resulting from co-administration with corticosteroids is a specific caution for patients with pre-existing cardiac, renal, or hepatic disease.

Androgen Receptor Agonism and Genomic Signaling

The active substance acts as an agonist at the Androgen Receptor (AR), a protein primarily found inside target cells. Upon binding, the activated complex enters the nucleus and modulates gene transcription by binding to DNA, which initiates the long-term synthesis of specific structural and signaling proteins. This key genomic mechanism is responsible for driving sustained anabolic signaling and resulting in the increase of skeletal muscle mass and the modulation of tissue function.

---

Metabolic Conversion and Dual Hormonal Action

In target tissues, testosterone undergoes enzymatic conversion by 5-alpha-reductase into the more potent androgen, DHT, and by Aromatase into the estrogen, estradiol (E2). This dual conversion ensures the simultaneous activation of both AR and the Estrogen Receptor (ER). This poly-mechanistic effect engages pathways that influence bone matrix deposition and the distribution of adipose tissue.

---

Feedback Modulation of Endocrine Control

A central mechanistic consequence is the activation of a negative feedback loop on the Hypothalamic-Pituitary-Gonadal (HPG) axis in the brain. The systemic presence of the active hormone suppresses the central release of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH). This central action demonstrates the drug’s influence on the control system that governs the body’s natural endocrine output.

How to Use Testosteron-Depot EIFELFANGO (Testosterone)

The official administration guidelines for this product define its use as a highly regulated, long-acting parenteral procedure, centered on a specific dosing range and a flexible schedule determined by hormone level monitoring.

---

Administration Scope

Instruction	Detail
Route of administration:	Intramuscular (IM) injection only, administered deeply into the gluteal muscle.
Dosing schedule:	Standard adult replacement dose is 250, mg (1 mL ampoule). Total monthly doses above 400, mg are generally not required due to the prolonged action.
Frequency and schedule:	Initial/Stimulation: 250, mg IM every two to three weeks. Maintenance: 250, mg IM every three to six weeks, according to individual serum levels.
Age-group rules:	Delayed Puberty: Dosing typically ranges from 50, mg to 200, mg IM every 2 to 4 weeks for a limited course duration of 4 to 6 months.
Special procedural conditions:	Administration must be performed by a healthcare professional. The oily solution must be injected very slowly, taking special care to avoid intravascular injection.
Dose adjustment logic:	Serum testosterone levels must be monitored at the end of the injection interval; levels below the normal range indicate a need to shorten the interval.

---

Resulting Procedural Structure

The official instructions establish a highly structured, long-acting parenteral protocol requiring professional oversight for its deep intramuscular administration. The medication is characterized by a standard 250, mg dose delivered at a variable, intermittent frequency, which is not fixed by a set schedule but is professionally adjusted based on laboratory monitoring of the patient's circulating testosterone levels. The contents of the ampoule must be injected immediately after opening.

Research Evidence / Overview of Studies

Summary of Core Efficacy Research

Testosterone Replacement Therapy (TRT) using injectable esters, such as those found in this depot formulation, is indicated for adult males with male hypogonadism, a condition confirmed by persistent clinical symptoms and two independent measurements of low serum testosterone levels.

Clinical trials, including the large-scale TRAVERSE study (Testosterone Replacement for Assessment of Long-term Vascular Events and Efficacy ResponSE), have assessed the effects of TRT. These studies typically enrolled middle-aged and older men with documented low testosterone and hypogonadal symptoms.

• Sexual Function and Mood: Studies have consistently shown that TRT is associated with improvements in sexual desire (libido) and erectile function in men with low testosterone. Some research also suggests a potential association with improved mood and decreased depressive symptoms.
• Physical Function and Body Composition: Research has explored the effect of testosterone on body structure and strength. Trials have reported increases in lean body mass (muscle mass) and bone mineral density in hypogonadal men. Functional outcomes, such as the distance walked in a specific timeframe, were also evaluated in patients with mobility limitations, with results indicating possible functional changes.

---

Safety Profile and Cardiovascular Risk

The TRAVERSE study, an FDA-mandated trial designed to assess cardiovascular safety, found that TRT was not associated with an increased risk of major adverse cardiovascular events (MACE), which include nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death, when compared to placebo in men with pre-existing cardiovascular risk factors. This finding provided reassurance regarding overall cardiovascular safety over the typical duration of treatment.

However, the same study reported a higher incidence of pulmonary embolism, acute kidney injury, and atrial fibrillation in the testosterone group, findings that warrant careful clinical consideration. Testosterone may also enhance the growth of existing prostate enlargement (BPH) or prostate cancer, necessitating pre-treatment screening and regular monitoring of prostate-specific antigen (PSA) levels.

Common questions about Testosteron-Depot EIFELFANGO (Testosterone) (FAQ)

Q: Is Testosteron-Depot EIFELFANGO a long-acting form of testosterone?

A: Yes, official product information classifies Testosteron-Depot EIFELFANGO as a depot preparation for injection. This specific oily solution is designed to create a reservoir, or depot, at the injection site, allowing the active hormone to be absorbed slowly into the bloodstream over a prolonged period.

Q: How quickly do people typically start to notice the effects of Testosteron-Depot EIFELFANGO?

A: Official regulatory documents detail the long-acting nature of the injection, with the dose interval being adjusted based on follow-up hormone level testing. While the frequency of injections can be several weeks apart, the onset of symptom improvement varies among individuals and is not defined by a single timeframe or guarantee in the official labeling.

Q: What is the difference between Testosteron-Depot EIFELFANGO and other testosterone injections?

A: Testosteron-Depot EIFELFANGO contains the active substance testosterone enanthate, which is an esterified form of testosterone. It is formulated as a deep intramuscular depot injection for sustained release. The official information specifies its active ingredient and form, but does not compare it to other specific testosterone injections, such as cypionate or undecanoate.

Q: What are the most common injection site side effects people report with this medication?

A: The official safety profile commonly lists injection site pain as an adverse reaction. Patients experiencing persistent or severe swelling, bruising, or pain at the injection site are advised in patient information leaflets to consult with their healthcare provider.

Q: Can this medication interact with common pain relievers or over-the-counter drugs?

A: Official regulatory documents specifically address interactions with oral anticoagulants, antidiabetics, and corticosteroids. While the official labeling does not specifically name common over-the-counter pain relievers, it is generally recommended to review all current medications with a healthcare provider before starting any new treatment.

Q: What kind of monitoring (blood tests) is required while on Testosteron-Depot EIFELFANGO?

A: The treatment protocol requires regular monitoring of several blood values. Key monitoring includes serum testosterone levels to guide the correct injection interval and Prostate-Specific Antigen (PSA) levels, especially in older men. Monitoring of haemoglobin and haematocrit (red blood cell count) is also required due to the risk of polycythemia.

Q: What should a patient know about using Testosteron-Depot EIFELFANGO if they have a history of heart problems?

A: Official regulatory information highlights that patients with pre-existing cardiac conditions require careful consideration. This is due to the potential for the drug to cause or worsen fluid retention (oedema), a risk that is also elevated when used with corticosteroids.

Q: What are the considerations for older men (over 65) using Testosteron-Depot EIFELFANGO?

A: For geriatric patients, regulatory warnings indicate an increased risk of prostatic issues, such as worsening of benign prostatic hyperplasia (BPH) and the promotion of undetected prostate cancer. Additionally, official documents state that there is insufficient long-term safety data for use in men over 65.

Q: Is it common to have fluid retention or swelling (oedema) with Testosteron-Depot EIFELFANGO?

A: Official information notes that the medicine can cause fluid retention (oedema), especially when co-administered with corticosteroids or in patients with cardiac, renal, or hepatic disease. However, its specific frequency when used alone is often not individually classified as a 'common' side effect in the official documents.

Q: How long does the medication stay active in the system after an injection?

A: The active substance is designed for a sustained-release effect, with absorption from the injection site occurring over a prolonged period. The injection frequency is adjusted based on an individual’s measured serum testosterone level at the end of the injection interval, which confirms the drug’s extended action in the body.

Q: Is Testosteron-Depot EIFELFANGO used to treat delayed puberty in young males?

A: Yes, regulatory documents mention that a varying lower-dose range is used for a limited course of treatment in young males with delayed puberty. However, use in all males under 18 years of age is generally restricted, and safety and efficacy have not been established for broad use in this population.

Q: Does Testosteron-Depot EIFELFANGO cause hair loss or increased body hair growth?

A: While the drug is an androgen, the official safety profile for this specific product commonly lists acne as a skin-related side effect. Changes in body hair growth (hirsutism) or hair loss are not listed among the most common reported adverse reactions.

Q: Are there any known issues with fertility while using Testosteron-Depot EIFELFANGO?

A: Official product information states that androgens suppress the central release of hormones that stimulate the testes, known as gonadotropins. This negative feedback loop can lead to oligospermia (low sperm count) and testicular atrophy due to the suppression of natural testosterone production.

Q: Is it normal to experience mood changes or irritability after starting this injection?

A: Regulatory documents list a range of psychiatric disorders as potential side effects, including mood changes, irritability, anxiety, and depression. Experiencing new or worsening emotional symptoms is noted to require professional monitoring by a healthcare provider.

Q: What are the signs that the dosage of Testosteron-Depot EIFELFANGO might be too high?

A: Signs that the testosterone level may be too high include excessive red blood cell count (polycythemia), persistent or painful erections (priapism), and emotional changes like nervousness or anxiety. Long-term use at excessively high doses is associated with the risk of hepatic neoplasms (liver tumours).

Q: What is the typical duration of treatment with Testosteron-Depot EIFELFANGO?

A: For adult male hypogonadism, this treatment is a form of replacement therapy and is typically considered to be a long-term or chronic medical treatment. The duration is not for a set period but is maintained as long as the underlying hypogonadal condition persists and is supported by ongoing monitoring.

Q: Can Testosteron-Depot EIFELFANGO be used by people with a history of migraines or epilepsy?

A: Official warnings state that the medicine should be used with caution in patients with a history of epilepsy. This caution relates to the drug's potential to cause fluid retention, which could theoretically exacerbate the condition. Migraine has also been reported as an uncommon side effect.

Q: Are there specific storage instructions for Testosteron-Depot EIFELFANGO ampoules?

A: Yes, official product information requires the medicine to be stored below 30 C and kept in the original package to protect it from light. The solution must be clear and administered immediately after the ampoule is opened.

Q: What happens when treatment with Testosteron-Depot EIFELFANGO is stopped?

A: Because the treatment works by suppressing the body's natural hormone production (the HPG axis), abrupt discontinuation may lead to a temporary return to a hypogonadal state. Symptoms associated with low testosterone, such as fatigue, low libido, and depression, may temporarily reappear.

Q: Is it normal to feel a temporary energy boost right after the injection?

A: The injection method results in a peak concentration of testosterone in the blood shortly after administration, followed by a gradual decline. Although a specific 'energy boost' is not listed as a side effect, this peak level is the physiological basis for a temporary feeling of increased effect before the levels settle into the therapeutic range.

Q: What is the significance of the 'Depot' in the drug name?

A: The term 'Depot' signifies a sustained-release preparation. It refers to the oily formulation that creates a localized reservoir of the drug within the muscle, allowing the active ingredient to be absorbed slowly and maintain therapeutic levels over an extended period.

Q: Are there any studies or clinical trials confirming the long-term safety of this type of testosterone therapy?

A: Official regulatory labels indicate that there is limited data from long-term clinical trials regarding the safety and efficacy of prolonged use in certain populations, particularly geriatric males over 65 years of age. This warrants ongoing monitoring and careful consideration of individual risks.

Q: Can using Testosteron-Depot EIFELFANGO affect the results of certain lab tests, like thyroid tests?

A: Yes, official drug information states that androgens can cause a decrease in the serum concentration of thyroxine-binding globulin (TBG). This can lead to a decrease in total T4 levels and potentially alter the results of certain thyroid function tests, although free thyroid hormone levels are generally unaffected.

Testosteron-Depot EIFELFANGO, a testosterone enanthate solution, must be stored under specific conditions to maintain its effectiveness.

Storage Requirements

The medicine must be stored below 30 C and kept out of the sight and reach of children. The ampoules or syringes must remain in the original folding box to protect from light.

Before use, the solution must be visually inspected; it should only be used if it is clear and free from particles. The injection must be administered immediately after the container is opened, and must not be used after the expiry date.

Disposal

Unused product or waste material must be disposed of in accordance with local regulatory requirements. This medicine should not be discarded via wastewater or household waste.